Table 2.
Univariate and multivariate analysis of predictors of hormonal therapy discontinuation among women diagnosed with breast cancer and treated with adjuvant hormonal therapy, MHS, 2000-2007
| Univariate |
Multivariate |
|||||
|---|---|---|---|---|---|---|
| Covariate | HR | 95% CI | p | HR | 95% CI | p |
| Age | ||||||
| ≤45 years | 1.00 | 1.00 | ||||
| 45.01–55 years | 0.57 | 0.48–0.68 | 0.00 | 0.65 | 0.54–0.79 | 0.00 |
| 55.01–65 years | 0.47 | 0.39–0.57 | 0.00 | 0.59 | 0.47–0.74 | 0.00 |
| 65.01–75 years | 0.49 | 0.40–0.60 | 0.00 | 0.66 | 0.51–0.86 | 0.00 |
| 75.01–85 years | 0.62 | 0.48–0.80 | 0.00 | 0.69 | 0.49–0.97 | 0.03 |
| 85.01+ years | 0.82 | 0.47–1.44 | 0.50 | 0.74 | 0.40–1.37 | 0.34 |
| SES | ||||||
| Lowest quartile | 1.00 | 1.00 | ||||
| Second quartile | 0.98 | 0.81–1.18 | 0.82 | 0.96 | 0.79–1.16 | 0.67 |
| Third quartile | 1.15 | 0.96–1.36 | 0.13 | 1.06 | 0.88–1.27 | 0.57 |
| Highest quartile | 1.01 | 0.83–1.22 | 0.94 | 0.89 | 0.72–1.11 | 0.30 |
| Birth country | ||||||
| Israel | 1.00 | 1.00 | ||||
| Europe | 0.82 | 0.72–0.94 | 0.01 | 0.92 | 0.78–1.08 | 0.31 |
| Asia/Africa | 0.70 | 0.54–0.90 | 0.01 | 0.86 | 0.65–1.14 | 0.29 |
| Other/unknown | 0.75 | 0.53–1.05 | 0.09 | 0.84 | 0.58–1.21 | 0.35 |
| District | ||||||
| Central | 1.00 | 1.00 | ||||
| Southern | 0.81 | 0.65–1.02 | 0.07 | 0.82 | 0.64–1.05 | 0.12 |
| Northern | 0.94 | 0.77–1.15 | 0.55 | 0.96 | 0.77–1.19 | 0.69 |
| Sharon | 0.87 | 0.72–1.06 | 0.17 | 0.85 | 0.69–1.04 | 0.11 |
| Jerusalem area | 0.84 | 0.69–1.01 | 0.06 | 0.84 | 0.68–1.03 | 0.09 |
| Other | 2.13 | 1.59–2.85 | 0.00 | |||
| BMI | ||||||
| Underweight | 2.07 | 1.70–2.52 | 0.00 | 2.34 | 1.85–2.97 | 0.00 |
| Normal | 1.00 | 1.00 | ||||
| Overweight | 0.84 | 0.71–0.99 | 0.03 | 0.96 | 0.81–1.15 | 0.68 |
| Obese | 0.82 | 0.69–0.98 | 0.03 | 1.02 | 0.84–1.24 | 0.86 |
| Smoking history | ||||||
| Current | 1.26 | 1.00–1.58 | 0.05 | 1.19 | 0.93–1.52 | 0.16 |
| Past | 1.10 | 0.73–1.65 | 0.65 | 1.13 | 0.74–1.73 | 0.57 |
| Never | 1.00 | 1.00 | ||||
| Other/unknown | 1.80 | 1.38–2.33 | 0.00 | 1.45 | 1.07–1.97 | 0.02 |
| Initial treatment | ||||||
| Tamoxifen | 1.00 | 1.00 | ||||
| AI | 1.10 | 0.83–1.45 | 0.52 | 1.15 | 0.85–1.55 | 0.38 |
| Year of initial treatment | ||||||
| 2000 | 1.00 | 1.00 | ||||
| 2001 | 1.25 | 0.90–1.73 | 0.19 | 1.15 | 0.81–1.64 | 0.44 |
| 2002 | 1.12 | 0.81–1.57 | 0.49 | 1.09 | 0.76–1.56 | 0.63 |
| 2003 | 0.99 | 0.71–1.40 | 0.97 | 1.07 | 0.74–1.55 | 0.71 |
| 2004 | 1.07 | 0.77–1.50 | 0.68 | 1.05 | 0.73–1.52 | 0.79 |
| 2005 | 0.93 | 0.67–1.29 | 0.67 | 1.02 | 0.71–1.45 | 0.93 |
| 2006 | 1.01 | 0.73–1.39 | 0.96 | 1.15 | 0.81–1.63 | 0.44 |
| 2007 | 1.07 | 0.77–1.47 | 0.69 | 1.17 | 0.82–1.66 | 0.39 |
| 2008 | 1.19 | 0.83–1.71 | 0.34 | 1.33 | 0.90–1.96 | 0.15 |
| Hypertension | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 0.68 | 0.59–0.79 | 0.00 | 0.74 | 0.62–0.89 | 0.00 |
| Osteoporosis | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 0.76 | 0.62–0.93 | 0.01 | 0.84 | 0.67–1.05 | 0.12 |
| Chronic kidney disease | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 0.93 | 0.73–1.19 | 0.55 | 1.09 | 0.83–1.44 | 0.54 |
| Cardiovascular disease | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 0.90 | 0.73–1.12 | 0.36 | 1.11 | 0.87–1.42 | 0.41 |
| Diabetes mellitus | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 0.79 | 0.64–0.98 | 0.03 | 1.02 | 0.80–1.29 | 0.90 |